About the Authors

Vidya P. Narayanaswamy

Affiliation Synedgen, Inc., Claremont, California, United States of America

Scott Giatpaiboon

Affiliation Synedgen, Inc., Claremont, California, United States of America

Shenda M. Baker

Affiliation Synedgen, Inc., Claremont, California, United States of America

William P. Wiesmann

Affiliation Synedgen, Inc., Claremont, California, United States of America

John J. LiPuma

Affiliation University of Michigan, Department of Pediatrics and Communicable Diseases, Ann Arbor, Michigan, United States of America

Stacy M. Townsend

st@synedgen.com

Affiliation Synedgen, Inc., Claremont, California, United States of America

Competing Interests

I have read the journal's policy and the authors of this manuscripts have the following competing interests: VNP SG SMT SMB and WPW are paid employees of Synedgen, SMT SMB and WPW have ownership and patents affiliated with Synedgen, and SMB and WPW are Board members. The glycopolymer used in this study is protected by US Patent number 8,119,780 B2 and others pending in development of drug products to treat cystic fibrosis associated lung infections and related indications. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Author Contributions

Conceptualization: SMT SMB WPW. Data curation: VPN. Formal analysis: VPN SMT. Funding acquisition: SMB WPW. Investigation: VPN SG. Methodology: SMT. Project administration: SMT. Resources: JJL. Supervision: SMT. Validation: VPN SMB SMT. Visualization: VPN SMT. Writing – original draft: VPN SMT. Writing – review & editing: SMT SMB JJL.